reports
Molecular Templates Presents Interim Data from MT-6402 Phase I Study i...
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Result...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023. Company Highlights Durable si...
Molecular Templates Announces $9.5 Million Private Placement Offering ...
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced today it has entered into a definitive amended and restated secu...
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. Provides Interim Update Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, toda...
Universal Display Corp: 1 director
A director at Universal Display Corp sold 7,000 shares at 171.324USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare L...
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference. Oppenheimer 34rd Annual Healthcare Conference, February 13 – 14 Format: Virtual PresentationDate: Wednesday, February 14, 2024Time: ...
- MarketLine Department
Catalent Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances
Summary Marketline's Catalent Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Catalent Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports o...
- MarketLine Department
Catalent Inc - Company Profile and SWOT Analysis
Summary Catalent Inc - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Catalent Inc (Catalent) provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The company offers complex advanced formulation delivery technol...
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
MTDR MATADOR RESOURCES COMPANY
MACK MERRIMACK PHARMACEUTICALS INC
HUBB HUBBELL INCORPORATED CLASS B
I3N CHART INDUSTRIES INC.
GPRE GREEN PLAINS INC.
GLP GLOBAL PARTNERS LP
CTSO CYTOSORBENTS
ASA ASA
TEX TEREX CORPORATION
HRTG HERITAGE INSURANCE HOLDINGS INC.
ADC AGREE REALTY CORPORATION
HTLD HEARTLAND EXPRESS INC.
NSA NATIONAL STORAGE AFFILIATES TRUST
PLAB PHOTRONICS INC.
WVE WAVE LIFE SCIENCES
CTHR CHARLES & COLVARD LTD.
PLSE PULSE BIOSCIENCES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
JFR NUVEEN FLOATING RATE INCOME FUND
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
FPF FIRST TRUST INTERMEDIATE DURATION PREFERRED AND INCOME FUND
RBB RBB BANCORP
LQDA LIQUIDIA CORPORATION
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
CHWY CHEWY
VTN INC.
DCTH INVESCO TRUST FOR INVESTMENT G
ENX DELCATH SYSTEMS
RYES EATON VANCE NEW YORK MUNICIPAL BOND FUND
RPTX PATRIOT MINEFINDERS INC.
GNSS REPARE THERAPEUTICS
SMMT GENASYS INC
RMBL SUMMIT THERAPEUTICS INC
VWE RUMBLEON INC
MPA VINTAGE WINE ESTATES INC
VPV BLACKROCK MUNIYIELD PENNSYLVANIA FD
ET INVESCO PA VALUE MUNI INC TST
SOL ENERGY TRANSFER LP
FTK RENESOLA LTD
CEV FLOTEK INDUSTRIES INC.
CUBA EATON VANCE CALIFORNIA MUN INC TRST
THE HERZFELD CARIBBEAN BASIN FUND
INC.
- Jonathan Moreland
GPRE GREEN PLAINS INC.
GLP GLOBAL PARTNERS LP
ASA ASA
CTHR CHARLES & COLVARD LTD.
PLSE PULSE BIOSCIENCES
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
VTN INVESCO TRUST FOR INVESTMENT G
DCTH DELCATH SYSTEMS
MPA BLACKROCK MUNIYIELD PENNSYLVANIA FD
VPV INVESCO PA VALUE MUNI INC TST
CEV EATON VANCE CALIFORNIA MUN INC TRST
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
MTDR MATADOR RESOURCES COMPANY
GABC GERMAN AMERICAN BANCORP
CRWS CROWN CRAFTS INC.
COMM COMMSCOPE HOLDING CO. INC.
BRKR BRUKER CORPORATION
BMY BRISTOL-MYERS SQUIBB COMPANY
ASA ASA
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
ENPH ENPHASE ENERGY INC.
HTLD HEARTLAND EXPRESS INC.
NSA NATIONAL STORAGE AFFILIATES TRUST
SCVL SHOE CARNIVAL INC.
UEIC UNIVERSAL ELECTRONICS INC.
CTHR CHARLES & COLVARD LTD.
PLSE PULSE BIOSCIENCES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NNBR NN
NXJ INC.
EQBK NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
MHI EQUITY BANCSHARES
FPF PIONEER MUNICIPAL HIGH INCOME TRUST
LAZY FIRST TRUST INTERMEDIATE DURATION PREFERRED AND INCOME FUND
AXR LAZYDAYS HOLDINGS
PCB AMREP
VTN PACIFIC CITY FINANCIAL CORP
GDRX INVESCO TRUST FOR INVESTMENT G
GBIO GOODRX HOLDINGS
SSSS INC.
ERAS GENERATION BIO
EMO SUTTER ROCK CAPITAL CORP.
BUKS ERASCA INC
VPV CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
SOL BUTLER NATIONAL CORP
CEV INVESCO PA VALUE MUNI INC TST
RENESOLA LTD
EATON VANCE CALIFORNIA MUN INC TRST
- Jonathan Moreland
- Jonathan Moreland
ASA ASA
HTLD HEARTLAND EXPRESS INC.
SCVL SHOE CARNIVAL INC.
CTHR CHARLES & COLVARD LTD.
PLSE PULSE BIOSCIENCES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LAZY LAZYDAYS HOLDINGS
VTN INVESCO TRUST FOR INVESTMENT G
GBIO GENERATION BIO
BMBL BUMBLE
MPA BLACKROCK MUNIYIELD PENNSYLVANIA FD
EMO CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
CEV EATON VANCE CALIFORNIA MUN INC TRST
- Jonathan Moreland
ITW ILLINOIS TOOL WORKS INC.
XRAY DENTSPLY SIRONA INC.
TNDM TANDEM DIABETES CARE INC
TCBI TEXAS CAPITAL BANCSHARES INC.
STAA STAAR SURGICAL CO.
SHBI SHORE BANCSHARES INC.
MRCY MERCURY SYSTEMS INC.
LMAT LEMAITRE VASCULAR INC.
KMPR KEMPER CORPORATION
GABC GERMAN AMERICAN BANCORP
BMY BRISTOL-MYERS SQUIBB COMPANY
AMRC AMERESCO
FMC FMC CORPORATION
HTLD HEARTLAND EXPRESS INC.
OESX ORION ENERGY SYSTEMS INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
CTHR CHARLES & COLVARD LTD.
PLSE PULSE BIOSCIENCES
VRNA VERONA PHARMA ADS
LAZY LAZYDAYS HOLDINGS
SPB SPECTRUM BRANDS HOLDINGS INC.
AXR AMREP
ATRI ATRION CORPORATION
ITRM ITERUM THERAPEUTICS
ZM ZOOM VIDEO COMMUNICATIONS
ATEX INC.
KSM ANTERIX
PTON DWS STRATEGIC MUNICIPAL INCOME TRUST
GDRX PELOTON INTERACTIVE
ONDS INC.
AGL GOODRX HOLDINGS
AUID INC.
AUGX ONDAS HOLDINGS
VWE AGILON HEALTH
VTRS INC.
SGHT IPSIDY INC.
VPV AUGMEDIX
CYT INC.
FTK VINTAGE WINE ESTATES INC
CEV VIATRIS INC
SEEL SIGHT SCIENCES INC
INVESCO PA VALUE MUNI INC TST
CYTEIR THERAPEUTICS INC
FLOTEK INDUSTRIES INC.
EATON VANCE CALIFORNIA MUN INC TRST
SENTINEL ELECTRONICS
- Jonathan Moreland
- Jonathan Moreland
MACK MERRIMACK PHARMACEUTICALS INC
DAR DARLING INGREDIENTS INC.
COMM COMMSCOPE HOLDING CO. INC.
AMRC AMERESCO
EVA ENVIVA PARTNERS LP
CTHR CHARLES & COLVARD LTD.
HAIN THE HAIN CELESTIAL GROUP
SNCR INC.
EML SYNCHRONOSS TECHNOLOGIES
HROW INC.
BW THE EASTERN COMPANY
GRWG HARROW HEALTH INC.
FBIO BABCOCK & WILCOX ENTERPRISES
U GROWGENERATION
FABIEN CORP
UNITY SOFTWARE INC.
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results...
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the third quarter of 2023. Eric Poma, PhD., Chief Executive and Chief...
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Eva...
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of ad...
Molecular Templates to Participate in Upcoming Investor Conferences
Molecular Templates to Participate in Upcoming Investor Conferences AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced participation in the following upcoming investor conferences: UBS Biopharma Conference 2023 Format: One-on-One MeetingsDates: November...
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to t...
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer. Dr. Voi possesses more than 35 years of wide-ranging drug development experience. Dr. Voi will begin his new role on October 2, 2023. Dr. Vo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.